市场概况

The global in vitro diagnostics (IVD) market is projected to reach USD 106.9 十亿 2029, growing at a CAGR of 2.5%. IVD provides precise diagnosis and point-of-care testing with advanced, cost-effective, and rapid tools. Key trends include low-volume sample analysis, 自动化, high-throughput analysis, rapid analysis times, small footprint, 低成本, portability, and disposability. The demand for advanced diagnostic services, driven by the global burden of chronic and infectious diseases, fuels market growth. 在美国, healthcare expenditure and disease awareness contribute to market growth, with infectious diseases like HIV, HSV, chlamydia, COVID-19, and monkeypox driving the demand for IVD diagnosis. Advancements in molecular diagnostics, including next-generation sequencing and CRISPR technology, enhance medical treatment outcomes and drive future market growth. Product launches and M&A strategies focus on developing innovative solutions, expanding production capacity, and diversifying portfolios. 全球范围, chronic and infectious diseases contribute to the demand for diagnostic services. Advanced technologies, such as AI-powered products and digital platforms, enhance efficiency and accuracy in the IVD field, propelling market growth.

该报告涵盖了市场规模和增长, 分割, 区域细分, 竞争格局, trends and strategies for global in vitro diagnostics market. 它提供了对市场的定量分析，使利益相关者能够利用当前的市场机会. 该报告还根据市场趋势和主要竞争对手的方法确定了最重要的机会和战略细分市场.

市场细分

市场根据多种因素进行细分, 包括产品 & 服务, 技术, 应用, 最终用户, 和地理.
产品: 试剂及耗材, instruments/analyzers, 软件和服务
技术: immuno and clinical chemistry, molecular diagnostics (MDx), 血液学, microbiology and cytology, POC testing, tissue diagnostics, 其他的
应用: 传染性疾病, 糖尿病, 心脏病学, 肿瘤学, 自身免疫性疾病, nephrology, drug testing, 其他的
最终用户: standard reference labs, hospital-affiliated labs, individuals, 诊所, 其他的

按地理位置细分
北美 – 美国, 加拿大
欧洲 - 德国, 法国, 英国, 意大利, 西班牙, 俄罗斯
亚太地区 – 中国, 日本, 印度, 韩国, 澳大利亚, 印度尼西亚, 马来西亚, 新加坡
拉丁美洲 – 巴西, 墨西哥, 阿根廷
中东 & 非洲 – 南非, 沙特阿拉伯, 火鸡

在 2022, reagents and consumables were the largest segments of the global in vitro diagnostics market, making up 66.1% 总市场份额. They play a crucial role in IVD procedures by transporting patient specimens for diagnosis, 治疗, and monitoring. The recurring use of reagents and consumables drives market growth, but there is limited innovation compared to analyzers. 然而, some companies have introduced new reagents for unique products, such as Sysmex’s concentrated reagents for hematology analyzers, gaining popularity and market share.

The immuno & clinical chemistry segment dominated the IVD market in 2022, 占 45.5% of the market share. Immunoassay and clinical chemistry technologies are widely used in diagnosing infectious and chronic diseases, driving growth. Clinical chemistry also detects cancer, 糖尿病, heart disease, and other health conditions.

Infectious diseases accounted for the largest market share (46.7%) in the global IVD market in 2022. COVID-19 significantly increased the demand for IVD tests, with billions conducted worldwide. Prevalence of infectious diseases like HIV and influenza drives the demand for IVD. Technological advancements in infectious disease diagnosis generate high revenue.

Standard reference labs were the dominant end-user in the global IVD market in 2022, 占 34.4% of the market share. They offer various IVD services, expanding in low- and middle-income countries. Hospitals also contribute significantly, serving as primary sources for disease diagnosis and treatment. Increasing hospitals, 基础设施, and healthcare expenditure fuel the demand for IVD practices.

North America had a 39.7% market share and dominated the global IVD market in 2022. Large patient population and healthcare expenditures contribute to its growth. Leading companies like Abbott and Bio-Rad Laboratories have a strong presence. Europe also experiences significant demand due to an aging population and prevalence of chronic and infectious diseases.

竞争格局

F. 罗氏霍夫曼公司, 雅培实验室, 赛默飞世尔科技, 公司, and Siemens Healthineers AG are prominent players in the global in vitro diagnostics market. They face competition from emerging market players. To expand their market share, these vendors employ strategies like inorganic growth and continuous product launches. Key companies profiled in this report include Abbott Laboratories, Accelerate Diagnostics, 公司, AccuBioTech Co., 有限公司, Agappe Diagnostics Ltd., 安捷伦科技, 公司, altona Diagnostics GmbH, Amoy Diagnostics Co., 有限公司, ARKRAY, 公司, 阿托莫诊断有限公司, 乙&E Bio-technology Co., 有限公司, 贝克顿, 迪金森公司, Biocartis Group NV, Biocept Inc, Biohit Oyj, bioLytical Laboratories Inc., Biomerica, 公司, bioMerieux S.A., Bio-Rad 实验室, 公司, Biosynex S.A., Biosystems, 公司, Bioway Biological Technology Co., 有限公司, Boule Diagnostics AB, 护理Dx, 公司, CellaVision AB, Chembio Diagnostics, 公司, Clindiag Systems Co., 有限公司, Contec Medical Systems Co., 有限公司, Convergent Technologies, 公司, 丘比特有限公司, 丹纳赫公司, DexCom, 公司, DIALAB GmbH, DiaSorin S.p.A., Diatron MI PLC, Dirui Industrial Co, Drucker Diagnostics, 有限责任公司, Dymind Biotechnology Co., 有限公司, Edan Instruments Inc., EKF Diagnostics Holdings plc, ELITech Group SAS, ERBA Diagnostics, 公司, F. 罗氏霍夫曼公司, Genetron Holdings Limited, Genrui Biotech Inc., 全息, 公司, Horiba, 有限公司, 照明公司, 公司, InTec PRODUCTS, INC., J. Mitra & 钴. 有限公司, Kilpest India Limited, Linear Chemicals, S.L.U., Maccura Biotechnology Co., 有限公司, Medsource Ozone Biomedicals Private Limited, Meril Life Sciences Pvt. 有限公司, Mindray Medical International Limited, MP生物医学, 有限责任公司, Nanjing Synthgene Medical Technology Co., 有限公司, 日本光电株式会社, Norma Instruments Zrt., NOWDiagnostics Inc., OPKO Health, 公司, OraSure Technologies, 公司, Ortho-Clinical Diagnostics, 公司, 珀金埃尔默, 公司, Prestige Diagnostics U.K. 有限公司, 凯杰公司, Quidel Corporation, Salofa Oy, Seasun Biomaterials Inc., Sekisui Medical Co., 有限公司, SFRI SAS, Shenzhen iCubio Biomedical Technology Co., 有限公司, Shenzhen Landwind Industry Co., 有限公司, Shenzhen Prokan Electronics Inc., 西门子卫生员AG, Sinocare Inc., Spinreact SA, SureScreen Diagnostics Ltd., Sysmex Corporation, 赛默飞世尔科技, 公司, 三一生物科技有限公司, Werfen, S.A., Xiamen Biotime Biotechnology Co., 有限公司, and Zhejiang Orient Gene Biotech Co., 有限公司.

最新行业发展

In March 2020, Abbott’s rapid diagnostic segment introduced a molecular test for COVID-19 detection using its ID NOW rapid point-of-care (POC) platform in the US.

Hoffmann-La Roche invested around $12.86 billion in R&D activities in fiscal year 2019 to develop innovative IVD test solutions.

在七月 2019, Siemens Healthineers successfully acquired Minicare B.V., a company specializing in point-of-care immunoassay testing technology. This acquisition has been integrated into Siemens Healthineers’ Diagnostics segment, enhancing its portfolio in rapid diagnostics.

报告范围

To analyze and forecast the market size of the global in vitro diagnostics market.
To classify and forecast the global in vitro diagnostics market based on product, 技术, 应用, 最终用户, 地区.
To identify drivers and challenges for the global in vitro diagnostics market.
检查合并等竞争性发展 & 收购, 协议, 合作与伙伴关系, ETC。, in the global in vitro diagnostics market.
To identify and analyze the profile of leading players operating in the global in vitro diagnostics market.

为什么选择这份报告

Gain a reliable outlook of the global in vitro diagnostics market forecasts from 2023 到 2029 跨场景.
确定投资的增长领域.
通过公司简介和市场数据领先于竞争对手.
Excel 格式的跨场景分析易用性的市场预估.
三个月的战略咨询和研究支持.
为单用户许可证提供打印验证.